SlideShare une entreprise Scribd logo
1  sur  60
Télécharger pour lire hors ligne
DR IMRAN GAFOOR
DR DEBASHISH DHAR
DEPTT OF CRITICAL CARE &
EMERGENCY MEDICINE
SIR GANGARAM HOSPITAL
 VAP : ventilator associated pneumonia is a
nosocomial pneumonia which develops in ICU
patients who have been tracheally
intubated/MV ≥ 2 days.
 VAT : ventilator associated tracheobronchitis,↑
in volume & purulence of resp secretions,fever
leucocytosis but no radiological infiltrates.
 HCAP : health care associated pneumonia.
RISK FACTORS
- hospitalzn. For ≥ 2 days within preceding 90
days,
- residencein nursing home or extended care
facility,
- home infusion therapy (antibiotics)
- chronic dialysis within 30 days,
- home wound care
- family member with MDR pathogens
 OTHER CLASSIFICATION :
PRIMARY ENDOGENOUS PNEUMONIA –
causative micro-organisms are isolated in surv-
eillance cultures on admission.
SECONDARY ENDOGENOUS PNEUMONIA-
causative micro-organisms later on colonize
oropharynx/GIT & reach lower resp tract
EXOGENOUS PNEUMONIA –
pt is not a previous carrier but colonised by
ventilator tubes ,bronchoscopes,humidifiers etc.
 EARLY vs LATE ONSET VAP :
EARLY ONSET (<4 days) –
antibiotic sensitive,better prognosis
LATE ONSET (5 days or more) –
MDR pathogens,increased mortality
There were no significant differences in the prevalence of
potential MDR pathogens associated with early-onset or late-
onset VAP, even in subjects with prior antibiotics. Empiric
therapy for early-onset VAP should also include agents likely to
be effective for potential MDR pathogens.
Respir Care. 2013 Jul;58(7):1220-5.
 TROVILLET et al found that two variables
were significant for predicting infection with
MDR VAP :
- mechanical ventilation ≥ 7 days
- prior antibiotic use esp broad spectrum
EPIDEMIOLOGY :
second most common nosocomial infection
but leading cause of attributable mortality
(33-50%)
 Incidence of HAP in india is 53.9%.
 Incidence of VAP in india is 8.95/1000
ventilator days.
 Mortality rate(attributable) is 37% - 47.3%
Park Es et al Am j inf control(2000)
0
1
2
3
4
5
6
7
8
9
10
jan feb mar apr may june july aug sep oct nov dec
Series 1
Column1
• It is estimated that 9-27% of patient undergoing
MV for > 2 days are affected by VAP.
. Cook et al demonstrated that,risk of VAP is 3%
on first 5 days of MV,2% from 5-10 days,& 1%
for remaining days.
MORTALITY : Several cross matching studies
have estimated that one third to half of all VAP
related deaths are result of
pseudomonas/acinetobacter pneumonia with
bacteremia.
- mortality is inversely related to adequacy of
initial empirical thereapy.
 - Correct & prompt treatment of pneumonia
results in better patient survival.
 - Inappropriate therapy is strongly associated
with worse survival.
 PATHOGENESIS :
* Pulmonary aspiration of colonised
(whether endo/exogenous) oropharyngeal
secretions across tracheal tube cuff is the
main pathogenic mechanism for development
of VAP.
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 * Tracheal intubation is the “conditio sine qua
non‖ for development of pneumonia because it
facilitates aspiration of pathogens & hinders
intrinsic respiratory defenses.
* Normally ETT has ‗HVLP‘ cuff,the potential
diameter of which is two to three times larger
than tracheal diameter,so,when tracheal cuff
is inflated within trachea,folds invaraibly form
along cuff surface,causing consistent
micro/macro aspiration of oropharyngeal
secretions.
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 * ETT is commonly made of PVC & bacteria
easily adhere to its internal surface forming a
complex structure called BIOFILM (sessile
bacteria embedded within a self produced
exopolysaccharide matrix)
* ETT biofilm is difficult to eradicate &
constitutes a persistent source of colonization.
SOURCES OF COLONIZATION :
- hands of ICU staff
- colonised bronchoscopes
- water supply
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
- respiratory equipments
- humidifiers
- ventilator temp sensors
- nebulizers
- contaminated environment.
- In critically ill patients endogenous oral flora
shifts early to aerobic gram – pathogens (pse-
udomonas,MRSA),pulmonary aspiration of
which leads to pneumonia.
 * Azarpazhooh et al showed that improved oral
hygiene & frequent professional oral health
care reduces progression or occurrence of
respiratory infection among patients in ICU.
* Orotracheal as compared to nasotracheal intu-
bation is associated with a decreased incidence
of sinusitis & thus VAP.
IMPAIREMENT OF RESPIRATORY
DEFENSES DURING CRITICAL ILLNESS
& TRACHEAL INTUBATION :
- no protection from adduction of true/false
vocal cords.
 - no protection from epiglottis
- cough not possible
- tracheally intubated patients have very low
muco ciliary velocity (0.8-1.4mm/min)–
higher risk for pulmonary complication.
- Temporary immunoparalysis during early
course of ICU stay (low levels of HLA-DR
expression on monocytes),may predispose to
colonization.
 ETIOLOGIC AGENTS :
* VAP is commonly caused by aerobic gram –
bacilli(peudomonos,E.coli,klebsiella,acine-
tobacter),while S.AUREUS is predominant
gram + organism.
• EPIC-II study confirmed that pseudomonos &
staph aureus are most common isolated patho-
gens in ICU.
UNDERLYING DISEASES :
- patients with COPD have higher risk for H.infl,
moraxella,pseudomonos,pneumococcus,
aspergillus
 In a study of nosocomial pneumonia in 51 ICU
patients in india,the most commonly isolated
organisms were
P.auroginosa(20%), Acinetobacter spp
(38%),klebsiella(23%),
MRSA(5%).The data also clearly demonstrate that the incidence
and prevalence of multidrug-resistant pathogens are
rising in Asian countries. A. baumannii–calcoaceticus
complex is emerging as a major pathogen in most of
the ICUs in these countries. MRSA, although present,
is not as big a problem as in the Western world;
doi:10.1016/j.ajic.2007.05.011
- Candida & aspergillus are m/c isolated fungi in
immunocompromised.
- Recent reviews show that candida in
respiratory samples demonstrate only
colonosation rather than pneumonia.
- Viruses causing VAP : HSV-I,CMV
- PREVENTIVE STRATEGIES FOR
NOSOCOMIAL PNEUMONIA :
1) Implementation ,as VAP bundle,of noso-
comial pneumonia preventive strategies
that have proven efficacy in reducing mo-
rbidity & mortality.
2) Implementation of education programmes
(respiratory care physicians & nurses being
primary recepients),& frequent performance
feedbacks & compliance assesment.
3) Strict alcohol based hand hygiene.
4) Avoidance of tracheal intubation & use of NIV
when indicated(acute exacebn. of COPD,
acute hypoxemic resp failure,immunocomp.
with pulmonary infiltrates)
-Recent reports emphasize role of NIV in
preventing re-intubation in recently extubated
pts at risk for relapse & respiratory failure.
5) Daily sedation vacation & implementation of
weaning protocols.
6) No ventilatory circuit tube changes unless soiled
or damaged.
7) Use of tracheal tubes with cuff made of novel
materials(polyurethane; & LVLP cuffs made of
silicone &latex) & shape(conical)
8)Application of low level PEEP(5-8cm
H2O)during tracheal intubation.
9) Use of silver coated ETT –
NASCENT trial concluded that silver coated
ETT has ↓ incidence of VAP,↓ mortality in pts
with VAP,is cost effective & has greatest
impact during first 10 days.
10) Aspiration of subglottic secretions(every 4-
6hrs)
11) Internal cuff pressure maintained within 25-30
cm H2O & carefully controlled during
transport of patients outside ICU.
12) Earlier tracheostomised pts (mean~7 days)
had shorter length of M/V & ICU stay,a ↓trend
towards pneumonia but no survival benefit as
compared to late tracheostomy(mean~14 days)
13) Routine saline instillation before tracheal
suctioning not recommended
14) Intubated pts should be kept in semi-
recumbent position(30-45°),rather than supine
to prevent aspiration;especially when enterally
fed.
15) Continuous lateral rotation of bed helps to
reduce extravascular lung water,improveV/Q
& enhance mobilization of secretions.
16) Post pyloric feeding in patients with impaired
gastric emptying
17) Risk of VAP associated with early enteral
feeding didn`t translate into ↑ risk of
death,so,early enteral feeding advised.
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
18) Stress ulcer prophylaxis in high risk
pts(coagulopathy,↑ duration of M/V,h/o
GI bleed.
19) Oral care with 2% chlorhexidine.
20) SELECTIVE CONTANINATION OF
DIGESTIVE TRACT (SDD) :
- consists of nonabsorbable antibio. Against
gram – (tobramycin.polymyxin E) + nystatin/
ampho B for candida administered into GI to
prevent oropharyngeal & gastric colonization.
- SDD reduces incidence of VAP & it‘s the only
strategy that has shown survival benefit
- SDD may promote growth of MRSA &
enterococcus,so,its highly recommended to
conduct appropriate surveillance of antibiotic
resistance pattern.
21) Use of probiotics is promising but additional
evidence required.
DIAGNOSIS :
- fever,tachycardia,leucocytosis – too
nonspecific
- tachypnea & consolidation – more specific
- in elderly & immunocomp. Lethargy &
confusion – main symptoms
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 An imaginary vertical line from the sternal notch to
the mouth, passing through the middle of the trachea
should be used as a surface landmark in order to
identify an orientation that could prevent
aspiration of oropharyngeal contents across the
cuff and improve drainage of airway scretions.
- Lateral slight-Trendelenburg position achieved with
the bed tilted few degrees below horizontal
Current Opinion in
Critical Care 2011,
17:57–63
- Chest x rays : difficult to interpret,limited
technical quality,misses subtle lung infiltrates.
- D/d for infiltrates :
- cardio/non cardiogenic pulmo. Edema
- atelectasis
- pulmonary contusions
- no radiographic sign has d/g accuracy of >68%
- Air bronchograms or alveolar opacities in pts
without ARDS co-related well with
pneumonia.
- Pleural effusion seen with H.infl>pneumoco
pneumonia
- diarrhea/abdominal pain – legionella p.
- Otitis media /pharyngitis – M.pneumonia
- Herpes labialis – pneumococcal
- Ecthyma gangrenosum – pseudomonos
septicemia
- NOTE : >30 bpm & Na < 130 during admission
predict poor outcome.
- CAVITATIONS :
- multiple cavitory nodules – rt sided
endocarditis
- rapid – gram (–) pneumonia
- subacute – anaerobic/mycobacterial
chronic – carcinoma,lymphoma,wegners
granulomatosis
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 CLINICAL PULMONARY INFECTION SCORE
(CPIS) :
CRITERION 0 1 2
tracheal secn. (-) not purulent purulent
x- ray infiltrates NO DIFFUSE LOCALISED
temp °C ≥36.5&≤38.4 ≥38.5&≤38.9 ≥39or≤36
leucocytes ≥4000&≤11000 <4000or>11000 +immature
neutro>50%
PaO2/FiO2 >240 or ARDS ≤240,noARDS
microbio (-) (+)
 CPIS ≥ 6 is regarded as threshold for
pneumonia but value remains to be validated.
 QUANTITATIVE CULTURES OF
ENDOTRACHEAL ASPIRATES MAY HAVE
AN ACCEPTABLE DIAGNOSTIC
ACCURACY.
 Current d/g threshold for tracheal aspirates is
10-10^ CFU/ml
― ― ― ― contaminants is
10 CFU/ml
― ― ― ― BAL is 10 CFU/ml
― ― ― ― PBS is 10³ CFU/ml
 - NON INFECTIOUS CAUSES OF
FEVER/INFILTRATES MIMICKING
NOSOCOMIAL PNEUMONIA :
- chemical pneumonitis
- atelectasis
- pulm embolism
- ARDS
- pulmomary hemorrhage
- lung contusion
- infiltrative tumour
- radiation pneumonitis
- drug reaction
- BOOP
 MOST RECENT IMPROVEMENTS IN D/G :
* direct antibiogram using E test strips applied
directly to resp samples have proved to be
reliable,effective & anticipate susceptibility by
≥ 48 hrs
* q PCR for mecA gene - for MRSA pneumonia
 Diagnostic strategies for hospital acquired
pneumonia :
- new or progressive chest infiltrate + atleast 2 of
3 clinical criteria(fever>38°c,leucocytosis or
leucopenia,purulent secretions) represent
beginning of diagnostic procedures
- clinical,non invasive semiquantative strategy
major drawback is high sensitivity of semi
quantative culture results which leads to over
estimation of incidence of nosocomial
pneumonia.
 Invasive and quantitative culturing strategy
for VAP :
- strongly recommended that d/g sampling of
respiratory tract be obtained before starting
any new antibiotic or changing previous
antimicrobial therapy.
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 STEP I : pt admitted/intubated for> 2
days,with no evident alternative foci of
infection with atleast 2 of 3 criteria :-
- fever > 37.8°c or hypothermia < 36°c
- TLC >12000/µl or <4000/µl
- purulent respiratory secretions
↓
with new infiltrates in chest x ray :
if yes(NP/VAP)||| if no (VAT)
STEP II : before initiating new empirical
antibiotics ,collect sample as follows :-
a) expectoration
b) tracheo-bronchial aspirate
c) BAL or mini –BAL
d) PBS
- 2 blood cultures
- pleural fluid sample for parapneumonic
effusion
- legionella/pneumococcal antigens in urine
- CBC/electrolytes/RFT/LFT/procal/ABG/
CRP
 STEP III : calculate CPIS (TO IMPROVE
OBJECTIVE ASSESMENT OF CLINICAL
PARAMETERS)
 TREATMENT :-
most frequently isolated organisms are
s.aureus,pseudomonos f/b enterobacteriacea(e
coli,klebsiella,enterobacter) then gram – as
acinetobacter,stenotrophomonas,burkholdheria &
lastly h influenzae,pneumococcus.
selection of antimicrobial tailored to local
prevelance of pathogens & antimicrobial
patterns of resistance.
1) Healthy subjects → pneumococcus,N menin.,
strepto pyogenes
2) acute/chronic co→pneumococc,H.influen,enterobac.
morbidities MSSA
3) 2 + antibiotics for→ESBL+ enterobac.,pseudomonos
3-5 days MRSA
4) 3 + antibiotics for→3 + non fermenting MDR GNB
7 days (peudomonos,stenotropho.,
acineto,candida)
 ATS/IDSA recommendations
 t/t based on timing of onset & risk factors for
MDR pathogens
 Risk Factors for Multidrug-Resistant
Pathogens
 Antimicrobial therapy in preceding 90 days
 Current hospitalization of at least 5 days
 High frequency of antibiotic resistance in the community
or in the specific hospital unit.
 Presence of risk factors for HCAP:
—Hospitalization for at least 2 days in the preceding 90
days
—Residence in a nursing home or extended care facility
—Home infusion therapy (including antibiotics)
—Chronic dialysis within 30 days
—Home wound care
—Family member with infection involving MDR pathogen
—Immunosuppressive disease and/or therapy
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 Initial Intravenous Adult doses of Antibiotics
Niederman M. et al, AJRCCM, 2005 Antibiotics
Dosage*
 Antipseudomonal cephalosporin
Cefepime 1-2g every 8-12h
Ceftazidime 2g every 8h
 Carbapenems
Imipenem 500mg every 6h or 1g every 8h
Meropenem 1g every 8h
 ß-Lactam/ ß-lactamase inhibitor
Piperacillin-tazobactam 4.5g every 6h
 Aminoglycosides
Gentamicin 5-7mg/kg per d
Tobramycin 7mg/kg per d
Amikacin 20mg/kg per d
 Antipseudomonal quinolones
Levofloxacin 750mg every d
Ciprofloxacin 400mg every 8h
 Vancomycin15mg/kg every 12hs
 Linezolid 600mg every 12h
 NOTE : for legionella → azithro + cipro/levoflox
- For resistant acineto → carbapenem or colistin +
tigecycline
- Nebulised colistin/tobramycin are used as
adjunct to systemic antibiotics in severe gram –
pneumonia,or,resistant bug eliminated only by
high level local drug conc.
- DURATION OF T/T :-
- majority of infections can be treated by 8 days
course,for non fermenting gram( – ) 14 days
- prolonged t/t is required in :
- legionella infection
- biofilms/prosthetic devices
- Tissue necrosis,abscess,empyema
- persistence of original infection(perforation,
endocarditis)
FAVOURABLE CLINICAL COURSE :-
- defervescence
- improved PaO2/FiO2
- ↓ CRP in 3-5 days
- third day CPIS < 6
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 - have focussed on ↓ cross transmission,pulm.
aspiration across ETT cuff, ↓ bacterial load in
oropharynx.
HIGHLY EFFECTIVE INTERVENTIONS :
1. SEMIRECUMBENT POSITION
2. SEDATION VACATION
3. DAILY ORAL CLEANSING WITH 2%
CHLORHEXIDINE
4. SUBGLOTTIC SECRETION DRAINAGE
 FERRER M (clinical infectious d/e 2010) :
- first study that validates 2005 ATS/IDSA
guidelines
- the study demonstrated worse microbial
prediction of 2005 guidelines,in comparison to
previous guidelines,in pts considerd at low risk
for acquiring MDR pathogens & similar low
prediction for fungi.
 Rather than focusing on VAP,
the new surveillance definition algorithm for
adults broadens the surveillance spectrum to
ventilator associated events(VAE)
A ventilator-associated condition
(VAC) is identified if, after a 2-day period of
stability or improvement on the ventilator, the
patient develops worsening oxygenation
(specific increases in levels of FIO2 or PEEP
over two or more calender years)
 Infection –related ventilator-associated
complication (IVAC) is identified in pts with
VAC who meet 2 additional criteria of clinical
signs of infection (specifically, defined values
for an abnormal temperature or white
count) and antibiotics prescribed for atleast
4 days. Identification of possible & probable
VAP within IVAC patients is determined by
purulent respiratory secretions and/or
specific laboratory and diagnostic tests. The
new algorithm remains complex and the
CDC is developing additional guidance
for its implementation
 Several features of the new VAE definition are
important. First, chest radiographs, a required
component in the current definition of VAP,
are no longer used in the definitions of
VAEs (including VAP).Second patients who
are receiving rescue ventilation are excluded.
Third patients must have a period of at
least 2 days of stability or improvent on
mechanical ventilation prior to
worsening.fourth,
VAC (and by extension, IVAC and VAP) is
limited to patients who have have
been mechanically ventilated for atleast
3 calendar days
 The VAP Surveillance Definition Working Group
recommended removing chest radiography from
the surveillance definition entirely.
 The CDC NHSN definition of VAP (and now
VAE, VAC, and IVAC) was developed to enable
surveillance of an important event; the CDC
specifically states that it should not be
used for clinical diagnosis.
AMERICAN JOURNAL OF CRITICAL
CARE, September 2012, Volume 21, No. 5
 VENTILATOR ASSOCIATED CONDITIONS :-
pt on mechanical ventilation > 2 days
↓
baseline period of stability or improvement,followed
by sustained period of worsening oxygenation
↓
VENTILATOR ASSOCIATED CONDITION(VAC)
↓
general objective evidence of inflammation/infection
↓
INFECTION RELATED VENTILATOR
ASSOCIATED COMPLICATION (IVAC)
↓
positive results of microbiological/laboratory testing
↓
possible or probable VAP
April 2013 CDC/NHSN Protocol
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN

Contenu connexe

Tendances

Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumoniadrcsaravind89
 
Ventilator associated pneumonia VAP
Ventilator associated pneumonia VAPVentilator associated pneumonia VAP
Ventilator associated pneumonia VAPAbdelrahman Al-daqqa
 
Fungal infections in the ICU
Fungal infections in the ICUFungal infections in the ICU
Fungal infections in the ICUAMITH SREEDHARAN
 
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku JosephVAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku JosephDr.Tinku Joseph
 
ventilator acquired pneumonia
ventilator acquired pneumonia ventilator acquired pneumonia
ventilator acquired pneumonia Hanadi Albasha
 
Scsu dawnjm ventilator associated pneumonia
Scsu dawnjm ventilator associated pneumoniaScsu dawnjm ventilator associated pneumonia
Scsu dawnjm ventilator associated pneumoniaLaurie Crane
 
Ventilator Associated Pneumonia (VAP) causes and preventive strategies
Ventilator Associated Pneumonia (VAP) causes and preventive strategiesVentilator Associated Pneumonia (VAP) causes and preventive strategies
Ventilator Associated Pneumonia (VAP) causes and preventive strategiesVeera Reddy Suravaram
 
Management of COVID-19 patients- Respiratory Failure
Management of COVID-19 patients- Respiratory Failure Management of COVID-19 patients- Respiratory Failure
Management of COVID-19 patients- Respiratory Failure Dr.Mahmoud Abbas
 
Oxygenation, Ventilation And Ventilator Management In The First 24 Hours
Oxygenation, Ventilation And Ventilator Management In The First 24 HoursOxygenation, Ventilation And Ventilator Management In The First 24 Hours
Oxygenation, Ventilation And Ventilator Management In The First 24 HoursDang Thanh Tuan
 
Aerosolized antibiotic
Aerosolized antibioticAerosolized antibiotic
Aerosolized antibiotickrishna kiran
 
High flow nasal cannula (hfnc) linkden
High flow nasal cannula (hfnc) linkdenHigh flow nasal cannula (hfnc) linkden
High flow nasal cannula (hfnc) linkdenAhmed AlGahtani, RRT
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumoniaBeena Philip
 
Pneumonia - Community Acquired Pneumonia (CAP)
Pneumonia  - Community Acquired Pneumonia (CAP)Pneumonia  - Community Acquired Pneumonia (CAP)
Pneumonia - Community Acquired Pneumonia (CAP)Arshia Nozari
 
Bundles to prevent ventilator associated pneumonia
Bundles to prevent ventilator associated pneumoniaBundles to prevent ventilator associated pneumonia
Bundles to prevent ventilator associated pneumoniapravin2k2
 

Tendances (20)

Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumonia
 
Ventilator associated pneumonia VAP
Ventilator associated pneumonia VAPVentilator associated pneumonia VAP
Ventilator associated pneumonia VAP
 
Fungal infections in the ICU
Fungal infections in the ICUFungal infections in the ICU
Fungal infections in the ICU
 
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku JosephVAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph
 
ventilator acquired pneumonia
ventilator acquired pneumonia ventilator acquired pneumonia
ventilator acquired pneumonia
 
vap.pptx
vap.pptxvap.pptx
vap.pptx
 
Scsu dawnjm ventilator associated pneumonia
Scsu dawnjm ventilator associated pneumoniaScsu dawnjm ventilator associated pneumonia
Scsu dawnjm ventilator associated pneumonia
 
Ventilator Associated Pneumonia (VAP) causes and preventive strategies
Ventilator Associated Pneumonia (VAP) causes and preventive strategiesVentilator Associated Pneumonia (VAP) causes and preventive strategies
Ventilator Associated Pneumonia (VAP) causes and preventive strategies
 
Acute eosinophilic pneumonia
Acute eosinophilic pneumoniaAcute eosinophilic pneumonia
Acute eosinophilic pneumonia
 
Management of COVID-19 patients- Respiratory Failure
Management of COVID-19 patients- Respiratory Failure Management of COVID-19 patients- Respiratory Failure
Management of COVID-19 patients- Respiratory Failure
 
Oxygenation, Ventilation And Ventilator Management In The First 24 Hours
Oxygenation, Ventilation And Ventilator Management In The First 24 HoursOxygenation, Ventilation And Ventilator Management In The First 24 Hours
Oxygenation, Ventilation And Ventilator Management In The First 24 Hours
 
Aerosolized antibiotic
Aerosolized antibioticAerosolized antibiotic
Aerosolized antibiotic
 
VENTILATOR ASSOCIATED PNEUMONIA.ppt
VENTILATOR ASSOCIATED PNEUMONIA.pptVENTILATOR ASSOCIATED PNEUMONIA.ppt
VENTILATOR ASSOCIATED PNEUMONIA.ppt
 
Cauti ppt
Cauti pptCauti ppt
Cauti ppt
 
High flow nasal cannula (hfnc) linkden
High flow nasal cannula (hfnc) linkdenHigh flow nasal cannula (hfnc) linkden
High flow nasal cannula (hfnc) linkden
 
Ventilator Associated Pneumonia
Ventilator Associated PneumoniaVentilator Associated Pneumonia
Ventilator Associated Pneumonia
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumonia
 
Pneumonia - Community Acquired Pneumonia (CAP)
Pneumonia  - Community Acquired Pneumonia (CAP)Pneumonia  - Community Acquired Pneumonia (CAP)
Pneumonia - Community Acquired Pneumonia (CAP)
 
Antifungals in icu
Antifungals in icuAntifungals in icu
Antifungals in icu
 
Bundles to prevent ventilator associated pneumonia
Bundles to prevent ventilator associated pneumoniaBundles to prevent ventilator associated pneumonia
Bundles to prevent ventilator associated pneumonia
 

En vedette

HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EDr Sandeep Kumar
 
Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )Bambang Fadhil
 
NationalLatest Updates to the Canadian VAP Guidelines - What's New?
NationalLatest Updates to the Canadian VAP Guidelines - What's New?NationalLatest Updates to the Canadian VAP Guidelines - What's New?
NationalLatest Updates to the Canadian VAP Guidelines - What's New?Canadian Patient Safety Institute
 
Difficult airway
Difficult airwayDifficult airway
Difficult airwayimran80
 
Anaesthesia machine
Anaesthesia machineAnaesthesia machine
Anaesthesia machineimran80
 
Vap getting started kit
Vap getting started kitVap getting started kit
Vap getting started kitNAIF AL SAGLAN
 
management of intraventricular hemorrhage with alteplase
management of intraventricular hemorrhage with alteplasemanagement of intraventricular hemorrhage with alteplase
management of intraventricular hemorrhage with alteplaseSurendra Patel
 
506544 634193328906940740
506544 634193328906940740506544 634193328906940740
506544 634193328906940740Logina Osman
 
approach to hyponatremia in children
approach to hyponatremia in childrenapproach to hyponatremia in children
approach to hyponatremia in childrendrranvijayrana
 
Fluid and blood resuscitation in abdominal trauma
Fluid and blood resuscitation in abdominal traumaFluid and blood resuscitation in abdominal trauma
Fluid and blood resuscitation in abdominal traumaimran80
 
Viral vaccines, An introduction
Viral vaccines, An introduction Viral vaccines, An introduction
Viral vaccines, An introduction Kaveh Haratian
 
Blood & blood products in icu
Blood & blood products in icuBlood & blood products in icu
Blood & blood products in icuimran80
 
Cardiopulmonary Cerebral Resuscitation (CPCR)
Cardiopulmonary Cerebral Resuscitation (CPCR) Cardiopulmonary Cerebral Resuscitation (CPCR)
Cardiopulmonary Cerebral Resuscitation (CPCR) upstatevet
 
Deep vein thrombosis
Deep vein thrombosisDeep vein thrombosis
Deep vein thrombosiscslonern
 
Febrile convulsions, Dr.Yousef Quda
Febrile convulsions, Dr.Yousef QudaFebrile convulsions, Dr.Yousef Quda
Febrile convulsions, Dr.Yousef QudaDryoussef Koda
 

En vedette (19)

HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8EHAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
HAP/VAP 2016 ATS/IDSA Guidelines. Our Data available at: https://rdcu.be/Mx8E
 
Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )
 
NationalLatest Updates to the Canadian VAP Guidelines - What's New?
NationalLatest Updates to the Canadian VAP Guidelines - What's New?NationalLatest Updates to the Canadian VAP Guidelines - What's New?
NationalLatest Updates to the Canadian VAP Guidelines - What's New?
 
Difficult airway
Difficult airwayDifficult airway
Difficult airway
 
Anaesthesia machine
Anaesthesia machineAnaesthesia machine
Anaesthesia machine
 
Vap getting started kit
Vap getting started kitVap getting started kit
Vap getting started kit
 
Ebp Vap
Ebp VapEbp Vap
Ebp Vap
 
management of intraventricular hemorrhage with alteplase
management of intraventricular hemorrhage with alteplasemanagement of intraventricular hemorrhage with alteplase
management of intraventricular hemorrhage with alteplase
 
506544 634193328906940740
506544 634193328906940740506544 634193328906940740
506544 634193328906940740
 
approach to hyponatremia in children
approach to hyponatremia in childrenapproach to hyponatremia in children
approach to hyponatremia in children
 
Fluid and blood resuscitation in abdominal trauma
Fluid and blood resuscitation in abdominal traumaFluid and blood resuscitation in abdominal trauma
Fluid and blood resuscitation in abdominal trauma
 
Viral vaccines, An introduction
Viral vaccines, An introduction Viral vaccines, An introduction
Viral vaccines, An introduction
 
Blood & blood products in icu
Blood & blood products in icuBlood & blood products in icu
Blood & blood products in icu
 
Cardiopulmonary Cerebral Resuscitation (CPCR)
Cardiopulmonary Cerebral Resuscitation (CPCR) Cardiopulmonary Cerebral Resuscitation (CPCR)
Cardiopulmonary Cerebral Resuscitation (CPCR)
 
CLABSI Prevention
CLABSI PreventionCLABSI Prevention
CLABSI Prevention
 
Deep vein thrombosis
Deep vein thrombosisDeep vein thrombosis
Deep vein thrombosis
 
approach to comatose child
approach to comatose childapproach to comatose child
approach to comatose child
 
Febrile convulsions, Dr.Yousef Quda
Febrile convulsions, Dr.Yousef QudaFebrile convulsions, Dr.Yousef Quda
Febrile convulsions, Dr.Yousef Quda
 
Hypocalcemia
HypocalcemiaHypocalcemia
Hypocalcemia
 

Similaire à VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN

Ventilator associated infections VAP
Ventilator associated infections VAP Ventilator associated infections VAP
Ventilator associated infections VAP Thair Abuaqeel
 
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...komalicarol
 
Prevention of pneunmonia in icu
Prevention of pneunmonia in icuPrevention of pneunmonia in icu
Prevention of pneunmonia in icuSami Eldahdouh
 
Lung Abscess, Pulmonolgy
Lung Abscess, PulmonolgyLung Abscess, Pulmonolgy
Lung Abscess, PulmonolgyVedica Sethi
 
SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia lastDr.Tarek Sabry
 
Managing pediatric Covid 19 client on ventilator
Managing pediatric Covid 19  client on ventilatorManaging pediatric Covid 19  client on ventilator
Managing pediatric Covid 19 client on ventilatorSmriti Arora
 
1 tuberculosis
1 tuberculosis1 tuberculosis
1 tuberculosisaaaj53
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
VENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptxVENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptxTolaOjo1
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumoniaBeena Philip
 
SARS COVID Various Researches
SARS COVID Various ResearchesSARS COVID Various Researches
SARS COVID Various ResearchesHeenaParveen23
 
Fungi( all fungal sinusitis & candidiasis)
Fungi( all fungal sinusitis & candidiasis)Fungi( all fungal sinusitis & candidiasis)
Fungi( all fungal sinusitis & candidiasis)Shekhar Krishna Debnath
 
Common diseases and affections of laboratroy rabbits, quick review guide
Common diseases and affections of laboratroy rabbits, quick review guideCommon diseases and affections of laboratroy rabbits, quick review guide
Common diseases and affections of laboratroy rabbits, quick review guidePavulraj Selvaraj
 

Similaire à VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN (20)

Hap
HapHap
Hap
 
Ventilator associated infections VAP
Ventilator associated infections VAP Ventilator associated infections VAP
Ventilator associated infections VAP
 
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...
A Rare Case Of Co-infection with Pulmonary tuberculosis and palatal actinomyc...
 
Prevention of pneunmonia in icu
Prevention of pneunmonia in icuPrevention of pneunmonia in icu
Prevention of pneunmonia in icu
 
Nosocomial infections
Nosocomial infectionsNosocomial infections
Nosocomial infections
 
Lung Abscess, Pulmonolgy
Lung Abscess, PulmonolgyLung Abscess, Pulmonolgy
Lung Abscess, Pulmonolgy
 
SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia last
 
Pneumonia Liza
Pneumonia LizaPneumonia Liza
Pneumonia Liza
 
Managing pediatric Covid 19 client on ventilator
Managing pediatric Covid 19  client on ventilatorManaging pediatric Covid 19  client on ventilator
Managing pediatric Covid 19 client on ventilator
 
1 tuberculosis
1 tuberculosis1 tuberculosis
1 tuberculosis
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
chronic Rhinosinusitis
chronic Rhinosinusitis chronic Rhinosinusitis
chronic Rhinosinusitis
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
VENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptxVENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptx
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumonia
 
SARS COVID Various Researches
SARS COVID Various ResearchesSARS COVID Various Researches
SARS COVID Various Researches
 
Nasal Polyposis.
Nasal Polyposis.Nasal Polyposis.
Nasal Polyposis.
 
Fungi( all fungal sinusitis & candidiasis)
Fungi( all fungal sinusitis & candidiasis)Fungi( all fungal sinusitis & candidiasis)
Fungi( all fungal sinusitis & candidiasis)
 
Common diseases and affections of laboratroy rabbits, quick review guide
Common diseases and affections of laboratroy rabbits, quick review guideCommon diseases and affections of laboratroy rabbits, quick review guide
Common diseases and affections of laboratroy rabbits, quick review guide
 

Plus de imran80

Tropical infections in Indian icu
Tropical infections in Indian icuTropical infections in Indian icu
Tropical infections in Indian icuimran80
 
ICU imaging
ICU imagingICU imaging
ICU imagingimran80
 
Radio ii
Radio iiRadio ii
Radio iiimran80
 
mock exercise icu practicals osce
 mock exercise icu practicals osce mock exercise icu practicals osce
mock exercise icu practicals osceimran80
 
basics of nutrition icu
basics of nutrition icubasics of nutrition icu
basics of nutrition icuimran80
 
Ards 2018
Ards 2018Ards 2018
Ards 2018imran80
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icuimran80
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shockimran80
 
Ventilation in obstructive airway disease
Ventilation in obstructive airway diseaseVentilation in obstructive airway disease
Ventilation in obstructive airway diseaseimran80
 
Atls tenth ed initial mm
Atls tenth ed initial mmAtls tenth ed initial mm
Atls tenth ed initial mmimran80
 
Hypertension in icu ppt
Hypertension in icu pptHypertension in icu ppt
Hypertension in icu pptimran80
 
Midazolam
MidazolamMidazolam
Midazolamimran80
 
Copy of vaporizers
Copy of vaporizersCopy of vaporizers
Copy of vaporizersimran80
 

Plus de imran80 (16)

Tropical infections in Indian icu
Tropical infections in Indian icuTropical infections in Indian icu
Tropical infections in Indian icu
 
ICU imaging
ICU imagingICU imaging
ICU imaging
 
Radio ii
Radio iiRadio ii
Radio ii
 
mock exercise icu practicals osce
 mock exercise icu practicals osce mock exercise icu practicals osce
mock exercise icu practicals osce
 
Ecmo
EcmoEcmo
Ecmo
 
basics of nutrition icu
basics of nutrition icubasics of nutrition icu
basics of nutrition icu
 
Ards 2018
Ards 2018Ards 2018
Ards 2018
 
Ards
ArdsArds
Ards
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icu
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Ventilation in obstructive airway disease
Ventilation in obstructive airway diseaseVentilation in obstructive airway disease
Ventilation in obstructive airway disease
 
Atls tenth ed initial mm
Atls tenth ed initial mmAtls tenth ed initial mm
Atls tenth ed initial mm
 
Circi
CirciCirci
Circi
 
Hypertension in icu ppt
Hypertension in icu pptHypertension in icu ppt
Hypertension in icu ppt
 
Midazolam
MidazolamMidazolam
Midazolam
 
Copy of vaporizers
Copy of vaporizersCopy of vaporizers
Copy of vaporizers
 

Dernier

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 

Dernier (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 

VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN

  • 1. DR IMRAN GAFOOR DR DEBASHISH DHAR DEPTT OF CRITICAL CARE & EMERGENCY MEDICINE SIR GANGARAM HOSPITAL
  • 2.  VAP : ventilator associated pneumonia is a nosocomial pneumonia which develops in ICU patients who have been tracheally intubated/MV ≥ 2 days.  VAT : ventilator associated tracheobronchitis,↑ in volume & purulence of resp secretions,fever leucocytosis but no radiological infiltrates.
  • 3.  HCAP : health care associated pneumonia. RISK FACTORS - hospitalzn. For ≥ 2 days within preceding 90 days, - residencein nursing home or extended care facility, - home infusion therapy (antibiotics) - chronic dialysis within 30 days, - home wound care - family member with MDR pathogens
  • 4.  OTHER CLASSIFICATION : PRIMARY ENDOGENOUS PNEUMONIA – causative micro-organisms are isolated in surv- eillance cultures on admission. SECONDARY ENDOGENOUS PNEUMONIA- causative micro-organisms later on colonize oropharynx/GIT & reach lower resp tract EXOGENOUS PNEUMONIA – pt is not a previous carrier but colonised by ventilator tubes ,bronchoscopes,humidifiers etc.
  • 5.  EARLY vs LATE ONSET VAP : EARLY ONSET (<4 days) – antibiotic sensitive,better prognosis LATE ONSET (5 days or more) – MDR pathogens,increased mortality There were no significant differences in the prevalence of potential MDR pathogens associated with early-onset or late- onset VAP, even in subjects with prior antibiotics. Empiric therapy for early-onset VAP should also include agents likely to be effective for potential MDR pathogens. Respir Care. 2013 Jul;58(7):1220-5.
  • 6.  TROVILLET et al found that two variables were significant for predicting infection with MDR VAP : - mechanical ventilation ≥ 7 days - prior antibiotic use esp broad spectrum EPIDEMIOLOGY : second most common nosocomial infection but leading cause of attributable mortality (33-50%)
  • 7.  Incidence of HAP in india is 53.9%.  Incidence of VAP in india is 8.95/1000 ventilator days.  Mortality rate(attributable) is 37% - 47.3% Park Es et al Am j inf control(2000)
  • 8. 0 1 2 3 4 5 6 7 8 9 10 jan feb mar apr may june july aug sep oct nov dec Series 1 Column1
  • 9. • It is estimated that 9-27% of patient undergoing MV for > 2 days are affected by VAP. . Cook et al demonstrated that,risk of VAP is 3% on first 5 days of MV,2% from 5-10 days,& 1% for remaining days. MORTALITY : Several cross matching studies have estimated that one third to half of all VAP related deaths are result of pseudomonas/acinetobacter pneumonia with bacteremia. - mortality is inversely related to adequacy of initial empirical thereapy.
  • 10.  - Correct & prompt treatment of pneumonia results in better patient survival.  - Inappropriate therapy is strongly associated with worse survival.  PATHOGENESIS : * Pulmonary aspiration of colonised (whether endo/exogenous) oropharyngeal secretions across tracheal tube cuff is the main pathogenic mechanism for development of VAP.
  • 12.  * Tracheal intubation is the “conditio sine qua non‖ for development of pneumonia because it facilitates aspiration of pathogens & hinders intrinsic respiratory defenses. * Normally ETT has ‗HVLP‘ cuff,the potential diameter of which is two to three times larger than tracheal diameter,so,when tracheal cuff is inflated within trachea,folds invaraibly form along cuff surface,causing consistent micro/macro aspiration of oropharyngeal secretions.
  • 14.  * ETT is commonly made of PVC & bacteria easily adhere to its internal surface forming a complex structure called BIOFILM (sessile bacteria embedded within a self produced exopolysaccharide matrix) * ETT biofilm is difficult to eradicate & constitutes a persistent source of colonization. SOURCES OF COLONIZATION : - hands of ICU staff - colonised bronchoscopes - water supply
  • 16. - respiratory equipments - humidifiers - ventilator temp sensors - nebulizers - contaminated environment. - In critically ill patients endogenous oral flora shifts early to aerobic gram – pathogens (pse- udomonas,MRSA),pulmonary aspiration of which leads to pneumonia.
  • 17.  * Azarpazhooh et al showed that improved oral hygiene & frequent professional oral health care reduces progression or occurrence of respiratory infection among patients in ICU. * Orotracheal as compared to nasotracheal intu- bation is associated with a decreased incidence of sinusitis & thus VAP. IMPAIREMENT OF RESPIRATORY DEFENSES DURING CRITICAL ILLNESS & TRACHEAL INTUBATION : - no protection from adduction of true/false vocal cords.
  • 18.  - no protection from epiglottis - cough not possible - tracheally intubated patients have very low muco ciliary velocity (0.8-1.4mm/min)– higher risk for pulmonary complication. - Temporary immunoparalysis during early course of ICU stay (low levels of HLA-DR expression on monocytes),may predispose to colonization.
  • 19.  ETIOLOGIC AGENTS : * VAP is commonly caused by aerobic gram – bacilli(peudomonos,E.coli,klebsiella,acine- tobacter),while S.AUREUS is predominant gram + organism. • EPIC-II study confirmed that pseudomonos & staph aureus are most common isolated patho- gens in ICU. UNDERLYING DISEASES : - patients with COPD have higher risk for H.infl, moraxella,pseudomonos,pneumococcus, aspergillus
  • 20.  In a study of nosocomial pneumonia in 51 ICU patients in india,the most commonly isolated organisms were P.auroginosa(20%), Acinetobacter spp (38%),klebsiella(23%), MRSA(5%).The data also clearly demonstrate that the incidence and prevalence of multidrug-resistant pathogens are rising in Asian countries. A. baumannii–calcoaceticus complex is emerging as a major pathogen in most of the ICUs in these countries. MRSA, although present, is not as big a problem as in the Western world; doi:10.1016/j.ajic.2007.05.011
  • 21. - Candida & aspergillus are m/c isolated fungi in immunocompromised. - Recent reviews show that candida in respiratory samples demonstrate only colonosation rather than pneumonia. - Viruses causing VAP : HSV-I,CMV - PREVENTIVE STRATEGIES FOR NOSOCOMIAL PNEUMONIA : 1) Implementation ,as VAP bundle,of noso- comial pneumonia preventive strategies that have proven efficacy in reducing mo- rbidity & mortality.
  • 22. 2) Implementation of education programmes (respiratory care physicians & nurses being primary recepients),& frequent performance feedbacks & compliance assesment. 3) Strict alcohol based hand hygiene. 4) Avoidance of tracheal intubation & use of NIV when indicated(acute exacebn. of COPD, acute hypoxemic resp failure,immunocomp. with pulmonary infiltrates) -Recent reports emphasize role of NIV in preventing re-intubation in recently extubated pts at risk for relapse & respiratory failure.
  • 23. 5) Daily sedation vacation & implementation of weaning protocols. 6) No ventilatory circuit tube changes unless soiled or damaged. 7) Use of tracheal tubes with cuff made of novel materials(polyurethane; & LVLP cuffs made of silicone &latex) & shape(conical) 8)Application of low level PEEP(5-8cm H2O)during tracheal intubation. 9) Use of silver coated ETT – NASCENT trial concluded that silver coated ETT has ↓ incidence of VAP,↓ mortality in pts with VAP,is cost effective & has greatest impact during first 10 days.
  • 24. 10) Aspiration of subglottic secretions(every 4- 6hrs) 11) Internal cuff pressure maintained within 25-30 cm H2O & carefully controlled during transport of patients outside ICU. 12) Earlier tracheostomised pts (mean~7 days) had shorter length of M/V & ICU stay,a ↓trend towards pneumonia but no survival benefit as compared to late tracheostomy(mean~14 days) 13) Routine saline instillation before tracheal suctioning not recommended
  • 25. 14) Intubated pts should be kept in semi- recumbent position(30-45°),rather than supine to prevent aspiration;especially when enterally fed. 15) Continuous lateral rotation of bed helps to reduce extravascular lung water,improveV/Q & enhance mobilization of secretions. 16) Post pyloric feeding in patients with impaired gastric emptying 17) Risk of VAP associated with early enteral feeding didn`t translate into ↑ risk of death,so,early enteral feeding advised.
  • 27. 18) Stress ulcer prophylaxis in high risk pts(coagulopathy,↑ duration of M/V,h/o GI bleed. 19) Oral care with 2% chlorhexidine. 20) SELECTIVE CONTANINATION OF DIGESTIVE TRACT (SDD) : - consists of nonabsorbable antibio. Against gram – (tobramycin.polymyxin E) + nystatin/ ampho B for candida administered into GI to prevent oropharyngeal & gastric colonization. - SDD reduces incidence of VAP & it‘s the only strategy that has shown survival benefit
  • 28. - SDD may promote growth of MRSA & enterococcus,so,its highly recommended to conduct appropriate surveillance of antibiotic resistance pattern. 21) Use of probiotics is promising but additional evidence required. DIAGNOSIS : - fever,tachycardia,leucocytosis – too nonspecific - tachypnea & consolidation – more specific - in elderly & immunocomp. Lethargy & confusion – main symptoms
  • 30.  An imaginary vertical line from the sternal notch to the mouth, passing through the middle of the trachea should be used as a surface landmark in order to identify an orientation that could prevent aspiration of oropharyngeal contents across the cuff and improve drainage of airway scretions. - Lateral slight-Trendelenburg position achieved with the bed tilted few degrees below horizontal Current Opinion in Critical Care 2011, 17:57–63
  • 31. - Chest x rays : difficult to interpret,limited technical quality,misses subtle lung infiltrates. - D/d for infiltrates : - cardio/non cardiogenic pulmo. Edema - atelectasis - pulmonary contusions - no radiographic sign has d/g accuracy of >68% - Air bronchograms or alveolar opacities in pts without ARDS co-related well with pneumonia. - Pleural effusion seen with H.infl>pneumoco pneumonia
  • 32. - diarrhea/abdominal pain – legionella p. - Otitis media /pharyngitis – M.pneumonia - Herpes labialis – pneumococcal - Ecthyma gangrenosum – pseudomonos septicemia - NOTE : >30 bpm & Na < 130 during admission predict poor outcome. - CAVITATIONS : - multiple cavitory nodules – rt sided endocarditis - rapid – gram (–) pneumonia - subacute – anaerobic/mycobacterial chronic – carcinoma,lymphoma,wegners granulomatosis
  • 34.  CLINICAL PULMONARY INFECTION SCORE (CPIS) : CRITERION 0 1 2 tracheal secn. (-) not purulent purulent x- ray infiltrates NO DIFFUSE LOCALISED temp °C ≥36.5&≤38.4 ≥38.5&≤38.9 ≥39or≤36 leucocytes ≥4000&≤11000 <4000or>11000 +immature neutro>50% PaO2/FiO2 >240 or ARDS ≤240,noARDS microbio (-) (+)
  • 35.  CPIS ≥ 6 is regarded as threshold for pneumonia but value remains to be validated.  QUANTITATIVE CULTURES OF ENDOTRACHEAL ASPIRATES MAY HAVE AN ACCEPTABLE DIAGNOSTIC ACCURACY.  Current d/g threshold for tracheal aspirates is 10-10^ CFU/ml ― ― ― ― contaminants is 10 CFU/ml ― ― ― ― BAL is 10 CFU/ml ― ― ― ― PBS is 10³ CFU/ml
  • 36.  - NON INFECTIOUS CAUSES OF FEVER/INFILTRATES MIMICKING NOSOCOMIAL PNEUMONIA : - chemical pneumonitis - atelectasis - pulm embolism - ARDS - pulmomary hemorrhage - lung contusion - infiltrative tumour - radiation pneumonitis - drug reaction - BOOP
  • 37.  MOST RECENT IMPROVEMENTS IN D/G : * direct antibiogram using E test strips applied directly to resp samples have proved to be reliable,effective & anticipate susceptibility by ≥ 48 hrs * q PCR for mecA gene - for MRSA pneumonia
  • 38.  Diagnostic strategies for hospital acquired pneumonia : - new or progressive chest infiltrate + atleast 2 of 3 clinical criteria(fever>38°c,leucocytosis or leucopenia,purulent secretions) represent beginning of diagnostic procedures - clinical,non invasive semiquantative strategy major drawback is high sensitivity of semi quantative culture results which leads to over estimation of incidence of nosocomial pneumonia.
  • 39.  Invasive and quantitative culturing strategy for VAP : - strongly recommended that d/g sampling of respiratory tract be obtained before starting any new antibiotic or changing previous antimicrobial therapy.
  • 41.  STEP I : pt admitted/intubated for> 2 days,with no evident alternative foci of infection with atleast 2 of 3 criteria :- - fever > 37.8°c or hypothermia < 36°c - TLC >12000/µl or <4000/µl - purulent respiratory secretions ↓ with new infiltrates in chest x ray : if yes(NP/VAP)||| if no (VAT)
  • 42. STEP II : before initiating new empirical antibiotics ,collect sample as follows :- a) expectoration b) tracheo-bronchial aspirate c) BAL or mini –BAL d) PBS - 2 blood cultures - pleural fluid sample for parapneumonic effusion - legionella/pneumococcal antigens in urine - CBC/electrolytes/RFT/LFT/procal/ABG/ CRP
  • 43.  STEP III : calculate CPIS (TO IMPROVE OBJECTIVE ASSESMENT OF CLINICAL PARAMETERS)  TREATMENT :- most frequently isolated organisms are s.aureus,pseudomonos f/b enterobacteriacea(e coli,klebsiella,enterobacter) then gram – as acinetobacter,stenotrophomonas,burkholdheria & lastly h influenzae,pneumococcus. selection of antimicrobial tailored to local prevelance of pathogens & antimicrobial patterns of resistance.
  • 44. 1) Healthy subjects → pneumococcus,N menin., strepto pyogenes 2) acute/chronic co→pneumococc,H.influen,enterobac. morbidities MSSA 3) 2 + antibiotics for→ESBL+ enterobac.,pseudomonos 3-5 days MRSA 4) 3 + antibiotics for→3 + non fermenting MDR GNB 7 days (peudomonos,stenotropho., acineto,candida)
  • 45.  ATS/IDSA recommendations  t/t based on timing of onset & risk factors for MDR pathogens
  • 46.  Risk Factors for Multidrug-Resistant Pathogens  Antimicrobial therapy in preceding 90 days  Current hospitalization of at least 5 days  High frequency of antibiotic resistance in the community or in the specific hospital unit.  Presence of risk factors for HCAP: —Hospitalization for at least 2 days in the preceding 90 days —Residence in a nursing home or extended care facility —Home infusion therapy (including antibiotics) —Chronic dialysis within 30 days —Home wound care —Family member with infection involving MDR pathogen —Immunosuppressive disease and/or therapy
  • 48.  Initial Intravenous Adult doses of Antibiotics Niederman M. et al, AJRCCM, 2005 Antibiotics Dosage*  Antipseudomonal cephalosporin Cefepime 1-2g every 8-12h Ceftazidime 2g every 8h  Carbapenems Imipenem 500mg every 6h or 1g every 8h Meropenem 1g every 8h  ß-Lactam/ ß-lactamase inhibitor Piperacillin-tazobactam 4.5g every 6h  Aminoglycosides Gentamicin 5-7mg/kg per d Tobramycin 7mg/kg per d Amikacin 20mg/kg per d  Antipseudomonal quinolones Levofloxacin 750mg every d Ciprofloxacin 400mg every 8h  Vancomycin15mg/kg every 12hs  Linezolid 600mg every 12h
  • 49.  NOTE : for legionella → azithro + cipro/levoflox - For resistant acineto → carbapenem or colistin + tigecycline - Nebulised colistin/tobramycin are used as adjunct to systemic antibiotics in severe gram – pneumonia,or,resistant bug eliminated only by high level local drug conc. - DURATION OF T/T :- - majority of infections can be treated by 8 days course,for non fermenting gram( – ) 14 days - prolonged t/t is required in : - legionella infection - biofilms/prosthetic devices
  • 50. - Tissue necrosis,abscess,empyema - persistence of original infection(perforation, endocarditis) FAVOURABLE CLINICAL COURSE :- - defervescence - improved PaO2/FiO2 - ↓ CRP in 3-5 days - third day CPIS < 6
  • 52.  - have focussed on ↓ cross transmission,pulm. aspiration across ETT cuff, ↓ bacterial load in oropharynx. HIGHLY EFFECTIVE INTERVENTIONS : 1. SEMIRECUMBENT POSITION 2. SEDATION VACATION 3. DAILY ORAL CLEANSING WITH 2% CHLORHEXIDINE 4. SUBGLOTTIC SECRETION DRAINAGE
  • 53.  FERRER M (clinical infectious d/e 2010) : - first study that validates 2005 ATS/IDSA guidelines - the study demonstrated worse microbial prediction of 2005 guidelines,in comparison to previous guidelines,in pts considerd at low risk for acquiring MDR pathogens & similar low prediction for fungi.
  • 54.  Rather than focusing on VAP, the new surveillance definition algorithm for adults broadens the surveillance spectrum to ventilator associated events(VAE) A ventilator-associated condition (VAC) is identified if, after a 2-day period of stability or improvement on the ventilator, the patient develops worsening oxygenation (specific increases in levels of FIO2 or PEEP over two or more calender years)
  • 55.  Infection –related ventilator-associated complication (IVAC) is identified in pts with VAC who meet 2 additional criteria of clinical signs of infection (specifically, defined values for an abnormal temperature or white count) and antibiotics prescribed for atleast 4 days. Identification of possible & probable VAP within IVAC patients is determined by purulent respiratory secretions and/or specific laboratory and diagnostic tests. The new algorithm remains complex and the CDC is developing additional guidance for its implementation
  • 56.  Several features of the new VAE definition are important. First, chest radiographs, a required component in the current definition of VAP, are no longer used in the definitions of VAEs (including VAP).Second patients who are receiving rescue ventilation are excluded. Third patients must have a period of at least 2 days of stability or improvent on mechanical ventilation prior to worsening.fourth, VAC (and by extension, IVAC and VAP) is limited to patients who have have been mechanically ventilated for atleast 3 calendar days
  • 57.  The VAP Surveillance Definition Working Group recommended removing chest radiography from the surveillance definition entirely.  The CDC NHSN definition of VAP (and now VAE, VAC, and IVAC) was developed to enable surveillance of an important event; the CDC specifically states that it should not be used for clinical diagnosis. AMERICAN JOURNAL OF CRITICAL CARE, September 2012, Volume 21, No. 5
  • 58.  VENTILATOR ASSOCIATED CONDITIONS :- pt on mechanical ventilation > 2 days ↓ baseline period of stability or improvement,followed by sustained period of worsening oxygenation ↓ VENTILATOR ASSOCIATED CONDITION(VAC) ↓ general objective evidence of inflammation/infection ↓ INFECTION RELATED VENTILATOR ASSOCIATED COMPLICATION (IVAC) ↓
  • 59. positive results of microbiological/laboratory testing ↓ possible or probable VAP April 2013 CDC/NHSN Protocol